Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.
|Videos|March 15, 2011
Vandetanib Advantages in Medullary Thyroid Cancer
Author(s)Peter Langmuir, MD
Advertisement
Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca on the Advantages of Vandetanib in Medullary Thyroid Cancer
Advertisement
Related to this article
Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Trastuzumab deruxtecan did not meet the prespecified efficacy criterion in HER2-low salivary gland carcinoma, though responses were observed in salivary duct carcinoma.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5